These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 9629878)

  • 1. Consensus regarding multiple day and rescue antiemetic therapy.
    De Mulder PH; Roila F; Kris MG; Marty MM
    Support Care Cancer; 1998 May; 6(3):248-52. PubMed ID: 9629878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized, single-blinded crossover study.
    Kimura H; Yamamoto N; Shirai T; Nishida H; Hayashi K; Tanzawa Y; Takeuchi A; Igarashi K; Inatani H; Shimozaki S; Kato T; Aoki Y; Higuchi T; Tsuchiya H
    Cancer Med; 2015 Mar; 4(3):333-41. PubMed ID: 25533447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reviewing current and emerging antiemetics for chemotherapy-induced nausea and vomiting prophylaxis.
    Natale JJ
    Hosp Pract (1995); 2015; 43(4):226-34. PubMed ID: 26308912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiemetic therapy for multiple-day chemotherapy and additional topics consisting of rescue antiemetics and high-dose chemotherapy with stem cell transplant: review and consensus statement.
    Einhorn LH; Grunberg SM; Rapoport B; Rittenberg C; Feyer P
    Support Care Cancer; 2011 Mar; 19 Suppl 1():S1-4. PubMed ID: 20505956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiemetic strategies for high-dose chemoradiotherapy-induced nausea and vomiting.
    Spitzer TR; Grunberg SM; Dicato MA
    Support Care Cancer; 1998 May; 6(3):233-6. PubMed ID: 9629875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal selection of antiemetics in children receiving cancer chemotherapy.
    Roila F; Aapro M; Stewart A
    Support Care Cancer; 1998 May; 6(3):215-20. PubMed ID: 9629872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Consensus proposal for 5HT3 antagonists in the prevention of acute emesis related to highly emetogenic chemotherapy. Dose, schedule, and route of administration.
    Gandara DR; Roila F; Warr D; Edelman MJ; Perez EA; Gralla RJ
    Support Care Cancer; 1998 May; 6(3):237-43. PubMed ID: 9629876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delayed emesis: moderately emetogenic chemotherapy (single-day chemotherapy regimens only).
    Roila F; Warr D; Aapro M; Clark-Snow RA; Einhorn L; Gralla RJ; Herrstedt J; Saito M; Tonato M
    Support Care Cancer; 2011 Mar; 19 Suppl 1():S57-62. PubMed ID: 21132332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of diazepam on delayed nausea and vomiting caused by anticancer agents].
    Tong FZ; Zhang JQ; Qiao XM; Mao YC; Meng FY; Liu HJ; Hui S; Zhu FX; Shu W; Hong J
    Gan To Kagaku Ryoho; 1998 Feb; 25(3):391-5. PubMed ID: 9492833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy-induced nausea and vomiting: antiemetic trials that impacted clinical practice.
    Trigg ME; Higa GM
    J Oncol Pharm Pract; 2010 Dec; 16(4):233-44. PubMed ID: 20085961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anticipatory nausea and vomiting in the era of 5-HT3 antiemetics.
    Morrow GR; Roscoe JA; Kirshner JJ; Hynes HE; Rosenbluth RJ
    Support Care Cancer; 1998 May; 6(3):244-7. PubMed ID: 9629877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of dexamethasone with 5-HT3-receptor antagonists for chemotherapy-induced nausea and vomiting.
    Perez EA
    Cancer J Sci Am; 1998; 4(2):72-7. PubMed ID: 9532406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double-blind, placebo-controlled study.
    Mizukami N; Yamauchi M; Koike K; Watanabe A; Ichihara K; Masumori N; Yamakage M
    J Pain Symptom Manage; 2014 Mar; 47(3):542-50. PubMed ID: 23856100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity--state of the art.
    Grunberg SM; Warr D; Gralla RJ; Rapoport BL; Hesketh PJ; Jordan K; Espersen BT
    Support Care Cancer; 2011 Mar; 19 Suppl 1():S43-7. PubMed ID: 20972805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I antiemetic study of MDL 73,147EF, a novel 5-hydroxytryptamine antagonist in cancer patients receiving emetogenic chemotherapy.
    Merrouche Y; Catimel G; Rebattu P; Dumortier A; Guastalla JP; O'Grady P; Clavel M
    Ann Oncol; 1994 Jul; 5(6):549-51. PubMed ID: 7918128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nausea and vomiting with high-dose chemotherapy and stem cell rescue therapy: a review of antiemetic regimens.
    Trigg ME; Inverso DM
    Bone Marrow Transplant; 2008 Oct; 42(8):501-6. PubMed ID: 18724391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative efficacy and safety of palonosetron with the first 5-HT3 receptor antagonists for the chemotherapy-induced nausea and vomiting: a meta-analysis.
    Jin Y; Sun W; Gu D; Yang J; Xu Z; Chen J
    Eur J Cancer Care (Engl); 2013 Jan; 22(1):41-50. PubMed ID: 22519361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy.
    Rapoport B; Schwartzberg L; Chasen M; Powers D; Arora S; Navari R; Schnadig I
    Eur J Cancer; 2016 Apr; 57():23-30. PubMed ID: 26851398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tropisetron (Navoban) alone and in combination with dexamethasone in the prevention of chemotherapy-induced emesis: the Nordic experience.
    Sorbe BG
    Semin Oncol; 1994 Oct; 21(5 Suppl 9):20-6. PubMed ID: 9113123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nausea and vomiting during the first 3 intercycle periods in chemo-naive cancer patients receiving moderately/highly emetogenic therapy.
    Pessi MA; Necchi A; Bossi P; Resteghini C; Giannatempo P; Ferrari L; Zilembo N; Ripamonti CI
    Tumori; 2015; 101(6):692-6. PubMed ID: 26108241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.